Role of N-cadherin in proliferation, migration, and invasion of germ cell tumours

Oncotarget

Volumn 6, Issue 32, 2015, Pages 33426-33437

  Bremmer, Felix ^a   Schallenberg, Simon ^a   Jarry, Hubertus ^b   Küffer, Stefan ^a   Kaulfuss, Silke ^a   Burfeind, Peter ^a   Strauß, Arne ^a   Thelen, Paul ^a   Radzun, Heinz Joachim ^a   Ströbel, Philipp ^a   Honecker, Friedemann ^c,d   Behnes, Carl Ludwig ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d Tumor Center ZeTuP   (Switzerland)

Author keywords

Cisplatin resistance; GCT cell lines; Germ cell tumours; N cadherin

Indexed keywords

BLOCKING ANTIBODY; CASPASE 3; MITOGEN ACTIVATED PROTEIN KINASE; NERVE CELL ADHESION MOLECULE; SMALL INTERFERING RNA; CADHERIN; CISPLATIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; GENE SILENCING; GERM CELL TUMOR; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; METASTASIS; MOUSE; NCCIT CELL LINE; NONHUMAN; NTERA 2 CELL LINE; PROTEIN EXPRESSION; SEMINOMA; TCAM 2 CELL LINE; TERATOMA; TUMOR CELL LINE; TUMOR XENOGRAFT; WESTERN BLOTTING; YOLK SAC TUMOR; ANIMAL; BAGG ALBINO MOUSE; CELL MOTION; DRUG RESISTANCE; GENETICS; METABOLISM; NEOPLASMS, GERM CELL AND EMBRYONAL; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; TESTICULAR NEOPLASMS; TUMOR INVASION;

ANIMALS; APOPTOSIS; CADHERINS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CISPLATIN; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASMS, GERM CELL AND EMBRYONAL; TESTICULAR NEOPLASMS;

EID: 84946028767     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5288     Document Type: Article

References (40)

1. Beyer J, Albers P, Altena R, Aparicio J, Bokemeyer C, Busch J, Cathomas R, Cavallin-Stahl E, Clarke NW, Classen J, Cohn-Cedermark G, Dahl AA, Daugaard G, De Giorgi U, De Santis M, De Wit M, et al. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 2013; 24:878-888.
2. Horwich A, Shipley J, Huddart R. Testicular germ-cell cancer. Lancet. 2006; 367:754-765.
3. Hoei-Hansen CE, Nielsen JE, Almstrup K, Sonne SB, Graem N, Skakkebaek NE, Leffers H, Rajpert-De Meyts E. Transcription factor AP-2gamma is a developmentally regulated marker of testicular carcinoma in situ and germ cell tumors. Clinical cancer research: an official journal of the American Association for Cancer Research. 2004; 10:8521-8530.
4. Bokemeyer C, Oechsle K, Honecker F, Mayer F, Hartmann JT, Waller CF, Bohlke I, Kollmannsberger C. Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 2008; 19:448-453.
5. Feldman DR, Bosl GJ, Sheinfeld J, Motzer RJ. Medical treatment of advanced testicular cancer. Jama. 2008; 299:672-684.
6. Einhorn LH, Brames MJ, Juliar B, Williams SD. Phase II study of paclitaxel plus gemcitabine salvage chemotherapy for germ cell tumors after progression following high-dose chemotherapy with tandem transplant. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2007; 25:513-516.
7. Oechsle K, Kollmannsberger C, Honecker F, Mayer F, Waller CF, Hartmann JT, Boehlke I, Bokemeyer C. Longterm survival after treatment with gemcitabine and oxaliplatin with and without paclitaxel plus secondary surgery in patients with cisplatin-refractory and/or multiply relapsed germ cell tumors. European urology. 2011; 60:850-855.
8. Nettersheim D, Gillis AJ, Looijenga LH, Schorle H. TGFbeta1, EGF and FGF4 synergistically induce differentiation of the seminoma cell line TCam-2 into a cell type resembling mixed non-seminoma. International journal of andrology. 2011; 34:e189-203.
9. Eini R, Stoop H, Gillis AJ, Biermann K, Dorssers LC, Looijenga LH. Role of SOX2 in the etiology of embryonal carcinoma, based on analysis of the NCCIT and NT2 cell lines. PloS one. 2014; 9:e83585.
10. Port M, Glaesener S, Ruf C, Riecke A, Bokemeyer C, Meineke V, Honecker F, Abend M. Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Molecular cancer. 2011; 10:52.
11. Angst BD, Marcozzi C, Magee AI. The cadherin superfamily: diversity in form and function. Journal of cell science. 2001; 114:629-641.
12. Potter E, Bergwitz C, Brabant G. The cadherin-catenin system: implications for growth and differentiation of endocrine tissues. Endocrine reviews. 1999; 20:207-239.
13. Stemmler MP. Cadherins in development and cancer. Molecular bioSystems. 2008; 4:835-850.
14. Gumbiner BM. Regulation of cadherin-mediated adhesion in morphogenesis. Nature reviews Molecular cell biology. 2005; 6:622-634.
15. El Sayegh TY, Kapus A, McCulloch CA. Beyond the epithelium: cadherin function in fibrous connective tissues. FEBS letters. 2007; 581:167-174.
16. Takeichi M. The cadherins: cell-cell adhesion molecules controlling animal morphogenesis. Development. 1988; 102:639-655.
17. Balsamo J, Arregui C, Leung T, Lilien J. The nonreceptor protein tyrosine phosphatase PTP1B binds to the cytoplasmic domain of N-cadherin and regulates the cadherin-actin linkage. The Journal of cell biology. 1998; 143:523-532.
18. Puch S, Armeanu S, Kibler C, Johnson KR, Muller CA, Wheelock MJ, Klein G. N-cadherin is developmentally regulated and functionally involved in early hematopoietic cell differentiation. Journal of cell science. 2001; 114:1567-1577.
19. Abutaily AS, Addis BJ, Roche WR. Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies. Journal of clinical pathology. 2002; 55:662-668.
20. Han AC, Peralta-Soler A, Knudsen KA, Wheelock MJ, Johnson KR, Salazar H. Differential expression of N-cadherin in pleural mesotheliomas and E-cadherin in lung adenocarcinomas in formalin-fixed, paraffin-embedded tissues. Human pathology. 1997; 28:641-645.
21. Laskin WB, Miettinen M. Epithelial-type and neuraltype cadherin expression in malignant noncarcinomatous neoplasms with epithelioid features that involve the soft tissues. Archives of pathology & laboratory medicine. 2002; 126:425-431.
22. Peralta Soler A, Knudsen KA, Tecson-Miguel A, McBrearty FX, Han AC, Salazar H. Expression of E-cadherin and N-cadherin in surface epithelial-stromal tumors of the ovary distinguishes mucinous from serous and endometrioid tumors. Human pathology. 1997; 28:734-739.
23. Markovic-Lipkovski J, Brasanac D, Muller GA, Muller CA. Cadherins and integrins in renal cell carcinoma: an immunohistochemical study. Tumori. 2001; 87:173-178.
24. Behnes CL, Hemmerlein B, Strauss A, Radzun HJ, Bremmer F. N-cadherin is differentially expressed in histological subtypes of papillary renal cell carcinoma. Diagnostic pathology. 2012; 7:95.
25. Bremmer F, Hemmerlein B, Strauss A, Burfeind P, Thelen P, Radzun HJ, Behnes CL. N-cadherin expression in malignant germ cell tumours of the testis. BMC clinical pathology. 2012; 12:19.
26. Jacobsen C, Honecker F. Cisplatin resistance in germ cell tumours: models and mechanisms. Andrology. 2015; 3:111-121.
27. Freemont AJ, Hoyland JA. Cell adhesion molecules. Clinical molecular pathology. 1996; 49:M321-330.
28. Mariotti A, Perotti A, Sessa C, Ruegg C. N-cadherin as a therapeutic target in cancer. Expert opinion on investigational drugs. 2007; 16:451-465.
29. Hazan RB, Phillips GR, Qiao RF, Norton L, Aaronson SA. Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis. The Journal of cell biology. 2000; 148:779-790.
30. Wang D, Lu P, Zhang H, Luo M, Zhang X, Wei X, Gao J, Zhao Z, Liu C. Oct-4 and Nanog promote the epithelialmesenchymal transition of breast cancer stem cells and are associated with poor prognosis in breast cancer patients. Oncotarget. 2014; 5:10803-10815.
31. Mueller T, Mueller LP, Luetzkendorf J, Voigt W, Simon H, Schmoll HJ. Loss of Oct-3/4 expression in embryonal carcinoma cells is associated with induction of cisplatin resistance. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2006; 27:71-83.
32. Gutekunst M, Mueller T, Weilbacher A, Dengler MA, Bedke J, Kruck S, Oren M, Aulitzky WE, van der Kuip H. Cisplatin hypersensitivity of testicular germ cell tumors is determined by high constitutive Noxa levels mediated by Oct-4. Cancer research. 2013; 73:1460-1469.
33. Tanaka H, Kono E, Tran CP, Miyazaki H, Yamashiro J, Shimomura T, Fazli L, Wada R, Huang J, Vessella RL, An J, Horvath S, Gleave M, Rettig MB, Wainberg ZA, Reiter RE. Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nature medicine. 2010; 16:1414-1420.
34. Hennenlotter J, Amend B, Vogel U, Renninger M, Springer C, Kuehs U, Stenzl A, Bedke J. Differential Akt signalling in non-seminomatous testicular germ cell tumors. Anticancer research. 2011; 31:3783-3788.
35. Nalla AK, Estes N, Patel J, Rao JS. N-cadherin mediates angiogenesis by regulating monocyte chemoattractant protein-1 expression via PI3K/Akt signaling in prostate cancer cells. Experimental cell research. 2011; 317:2512-2521.
36. Schweyer S, Soruri A, Meschter O, Heintze A, Zschunke F, Miosge N, Thelen P, Schlott T, Radzun HJ, Fayyazi A. Cisplatin-induced apoptosis in human malignant testicular germ cell lines depends on MEK/ERK activation. British journal of cancer. 2004; 91:589-598.
37. Perotti A, Sessa C, Mancuso A, Noberasco C, Cresta S, Locatelli A, Carcangiu ML, Passera K, Braghetti A, Scaramuzza D, Zanaboni F, Fasolo A, Capri G, Miani M, Peters WP, Gianni L. Clinical and pharmacological phase I evaluation of Exherin (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing solid tumours. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 2009; 20:741-745.
38. Yarom N, Stewart D, Malik R, Wells J, Avruch L, Jonker DJ. Phase I clinical trial of Exherin (ADH-1) in patients with advanced solid tumors. Current clinical pharmacology. 2013; 8:81-88.
39. Stewart DJ, Jonker DJ, Goel R, Goss G, Maroun JA, Cripps CM, Wells J, Wargin W, Malik RK, Peters WP. Final clinical and pharmacokinetic (PK) results from a phase I study of the novel N-cadherin (N-cad) antagonist, Exherin (ADH-1), in patients with refractory solid tumors stratified according to N-cad expression. Journal of Clinical Oncology ASCO Annual Meeting Proceedings (PostMeeting Edition). 2006; 24. Abstr 3016.
40. Eble JN, Sauter G, Epstein JI. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. 2004; (Lyon: IARC press).